Clinical Trials

159 enrolled 17 charts

Sarcoma

Gliosarcoma

NCT05987241 2026-04-22

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

992 enrolled

Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

135 enrolled

Melanoma

NCT06203600 2026-04-21

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

224 enrolled

Adenocarcinoma Of Esophagus

NCT02339571 2026-04-13

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

600 enrolled

Melanoma

NCT03952585 2026-04-13

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

384 enrolled 22 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT04929041 2026-04-13

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Phase 2/3 Suspended

427 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07392892 2026-04-13

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

840 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

280 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07221149 2026-04-02

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

690 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

420 enrolled

Uveal Melanoma, Melanoma

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

52 enrolled

Advanced or Metastatic Solid Malignancies

NCT03470922 2025-09-09

RELATIVITY-047

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT04695977 2025-09-05

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Phase 2/3 Terminated

20 enrolled 18 charts

Melanoma

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

20 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT04901988 2025-02-27

DETECTION

Phase 2/3 Terminated

8 enrolled

Melanoma

NCT04268888 2025-02-26

TACE-3

Phase 2/3 Suspended

522 enrolled

Carcinoma, Hepatocellular

NCT03366272 2025-01-28

NIVEAU

348 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

76 enrolled 16 charts

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02746796 2024-05-03

Study of ONO-4538 in Gastric Cancer

680 enrolled

Stomach Neoplasms

NCT03414983 2023-11-18

CheckMate 9X8

196 enrolled 26 charts

Colorectal Neoplasms

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Phase 2/3 Unknown

135 enrolled

Genitourinary

Prostatic Neoplasms

NCT05213312 2022-06-15

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Phase 2/3 Unknown

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT04044651 2020-01-09

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

Phase 2/3 Withdrawn